These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

628 related items for PubMed ID: 14519673

  • 1. Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B.
    Paterson PJ, Seaton S, Prentice HG, Kibbler CC.
    J Antimicrob Chemother; 2003 Nov; 52(5):873-6. PubMed ID: 14519673
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the Sensititre YeastOne colorimetric antifungal panel and Etest with the NCCLS M38-A method to determine the activity of amphotericin B and itraconazole against clinical isolates of Aspergillus spp.
    Martín-Mazuelos E, Pemán J, Valverde A, Chaves M, Serrano MC, Cantón E.
    J Antimicrob Chemother; 2003 Sep; 52(3):365-70. PubMed ID: 12917236
    [Abstract] [Full Text] [Related]

  • 3. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
    Kaya AD, Kiraz N.
    Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704
    [Abstract] [Full Text] [Related]

  • 4. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.
    Warn PA, Morrissey G, Morrissey J, Denning DW.
    J Antimicrob Chemother; 2003 Apr; 51(4):913-9. PubMed ID: 12654746
    [Abstract] [Full Text] [Related]

  • 5. Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma.
    Chen J, Li H, Li R, Bu D, Wan Z.
    J Antimicrob Chemother; 2005 Jan; 55(1):31-7. PubMed ID: 15563516
    [Abstract] [Full Text] [Related]

  • 6. Comparison of Sensititre YeastOne with the NCCLS M38-A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus.
    Guinea J, Peláez T, Alcalá L, Bouza E.
    Diagn Microbiol Infect Dis; 2006 Sep; 56(1):53-5. PubMed ID: 16650953
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. In vitro activities of amphotericin B and AmBisome against Aspergillus isolates recovered from Italian patients treated for haematological malignancies.
    Colozza C, Posteraro B, Santilli S, De Carolis E, Sanguinetti M, Girmenia C.
    Int J Antimicrob Agents; 2012 May; 39(5):440-3. PubMed ID: 22429723
    [Abstract] [Full Text] [Related]

  • 9. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli.
    Lionakis MS, Lewis RE, Torres HA, Albert ND, Raad II, Kontoyiannis DP.
    Diagn Microbiol Infect Dis; 2005 May; 52(1):15-20. PubMed ID: 15878437
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Correlation between the E test and the CLSI M-38 A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus.
    Guinea J, Peláez T, Alcalá L, Bouza E.
    Diagn Microbiol Infect Dis; 2007 Mar; 57(3):273-6. PubMed ID: 17141455
    [Abstract] [Full Text] [Related]

  • 12. Effect of pH on the in vitro activities of amphotericin B, itraconazole, and flucytosine against Aspergillus isolates.
    Te Dorsthorst DT, Mouton JW, van den Beukel CJ, van der Lee HA, Meis JF, Verweij PE.
    Antimicrob Agents Chemother; 2004 Aug; 48(8):3147-50. PubMed ID: 15273136
    [Abstract] [Full Text] [Related]

  • 13. Rapid method for testing the susceptibility of Aspergillus fumigatus to amphotericin B, itraconazole, voriconazole and posaconazole by assessment of oxygen consumption.
    Araujo R, Coutinho I, Espinel-Ingroff A.
    J Antimicrob Chemother; 2008 Dec; 62(6):1277-80. PubMed ID: 18824456
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effects of amphotericin B on Aspergillus flavus clinical isolates with variable susceptibilities to the polyene in an experimental model of systemic aspergillosis.
    Barchiesi F, Spreghini E, Sanguinetti M, Giannini D, Manso E, Castelli P, Girmenia C.
    J Antimicrob Chemother; 2013 Nov; 68(11):2587-91. PubMed ID: 23794598
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Antifungal susceptibilities of Aspergillus spp. strains isolated from invasive aspergillosis cases].
    Gürcan S, Tikveşli M, Eryildiz C, Evci C, Ener B.
    Mikrobiyol Bul; 2010 Apr; 44(2):273-8. PubMed ID: 20549962
    [Abstract] [Full Text] [Related]

  • 20. Poor efficacy of amphotericin B-based therapy in CNS aspergillosis.
    Schwartz S, Ruhnke M, Ribaud P, Reed E, Troke P, Thiel E.
    Mycoses; 2007 May; 50(3):196-200. PubMed ID: 17472616
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.